Avoiding Common Pitfalls in the IND and CTA Submission Process

[Fill out the form below to register]

Abstract: When planning an Investigational New Drug (IND) or Clinical Trial Authorization (CTA) submission, navigating FDA, EMA, and other regulations can be challenging and creating scientifically-sound strategies are essential. As submissions expand to multiple countries during later phase trials, greater challenges can arise if not prepared with knowledge of the requirements, proper time management, and defined roles for the team towards approval. 

Join us as experts in project management, medical writing, and regulatory operations discuss best practices for a successful submission process from start to finish. 

Attendees will learn:

  • Efficiencies for multi-country submissions 
  • Essential steps in pre-submission planning 
  • Timeline management and potential pitfalls 
  • How to define roles and responsibilities to avoid delays or confusion 
  • Structure and content of the submissions at various stages of development 
  • Navigating the country–specific regulatory requirements 
  • Post-submission maintenance and responsibilities 

Presenters:

Jessica Reed, PhD, Senior Manager, Project and Account Management  

Nicole Northrop, PhD, Manager, Regulatory and Medical Writing 

Allison Ward, MSA, MSEd, Senior Manager, Regulatory Operations 

Avoiding Common Pitfalls in the IND and CTA Submission Process

Register for the webinar

Suggested For You

perspectives

May 13th, 2026

Beyond Data Cleaning: A Strategic Shift for Clinical Data Management under ICH E6 (R3)

perspectives

May 5th, 2026

A Statistician's Reflection: FDA Guidance on Limiting Crossover in Oncology Studies 

perspectives

April 27th, 2026

From Stigma to Signal: The Executive Order, CNPV Vouchers, and What Comes Next for Psychedelics

perspectives

April 20th, 2026

The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain

perspectives

April 15th, 2026

Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks

perspectives

April 8th, 2026

Four Pillars of My Success as a Clinical Trial Transparency Specialist

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development